The majority of testicular tumors in children are of germ cell origin and the predominant pathologic type is the yolk sac carcinoma. Initial treatment of radical orchiectomy is not in question. However, because of its presumed less virulent character, confusion remains as to adjunctive treatment for yolk sac carcinoma. Recently we experienced a case of advanced yolk sac carcinoma treated with multiple systemic chemotherapy regimen.
Child ; Drug Therapy* ; Germ Cells ; Humans ; Orchiectomy ; Testicular Neoplasms ; Yolk Sac*

We have experienced 3 cases of testicular tumors since last 2 years, from June, 1981 to May, 1983. two cases were embryonal Ca. occurred in 22 years old male and 2 1/2 years old male respectively and another one was seminoma case occurred in 33 years old male. All of them were undergone inguinal orchiectomy and the seminoma case has been taken anti-tumor chemotherapy with radiation therapy and still alive. The adult embryonal Ca. case expired 3 months after operation and the child embryonal Ca. case is alive under observation.
Adult ; Child ; Drug Therapy ; Humans ; Male ; Orchiectomy ; Seminoma ; Testicular Neoplasms* ; Young Adult

A testicular Sertoli cell tumor is a very rare, usually benign, testicular neoplasm. Of the total number of reported Sertoli cell tumors, only 30 cases were malignant. Usually, these patients have a history of a slowly growing scrotal mass and gynecomastia. These neoplasms vary greatly in size and in their microscopic appearances. A radical inguinal orchiectomy is the initial treatment, with the efficacy of chemotherapy or radiotherapy being controversial. They have an aggressive metastatic behavior and a poor prognosis. Herein, the case of 67-year-old man with a malignant Sertoli cell tumor is reported.
Aged ; Drug Therapy ; Gynecomastia ; Humans ; Male ; Orchiectomy ; Prognosis ; Radiotherapy ; Sertoli Cell Tumor* ; Testicular Neoplasms ; Testis*

Incidence of testicular tumor is 1-2% in all male tumor. Various series report that 3.6-11.6% of testicular tumor arise in patient with cryptorchidism or a history of cryptorchidism. But testicular tumors developed in suprapubic ectopic testis were reported rarely. Seminoma is one of the most radiosensitive tumor. However, the survival of patients with advanced tumor is poor. Therefore adjuvant systemic chemotherapy is essential for proper treatment of these patients. Recently we experienced a case of advanced seminoma resulted from suprapubic ectopic testis and treated by orchiectomy, systemic chemotherapy and radiation with good result.
Cryptorchidism ; Drug Therapy ; Humans ; Incidence ; Male ; Orchiectomy ; Seminoma* ; Testicular Neoplasms ; Testis*

Testicular tumors were reported sporadically in Korea. Seminomatous germ cell tumor is the most frequent tumor in the testis and it is treated highly effectively with irradiation and/or chemotherapy according to stage. Herein we report a relatively rare case of seminoma developed in abdominal cryptorchid testis of 28 years old male. which was treated with PVB chemotherapy after cytoreductive surgery. Histopathological examination revealed seminoma of stage II B(T3N2MO) by M.D. Anderson hospital classification Postoperative PVB chemotherapy was performed and the tumor was completely remitted at follow up study for 4 years.
Adult ; Classification ; Cryptorchidism ; Drug Therapy ; Follow-Up Studies ; Humans ; Korea ; Male ; Neoplasms, Germ Cell and Embryonal ; Seminoma* ; Testicular Neoplasms ; Testis*

Follow-up study was made on 14 patients of testicular who were treated at Severance hospital since 1972. The results are summarized as follows: 1. Among the 14 cases of testicular tumors, there were 7 cases of seminoma and 7 cases of nonseminomatous germ cell tumors(3 cases of embryonal cell carcinoma, 1 case of teratoma, 1 case of teratocarcinoma, 1 case of malignant lymphoma and 1 case of reticulum cell sarcoma.) 2. The median survival periods of 7 patients of seminoma was 35 months(range 6 to 113 months). the median survival periods of 7 patients of nonseminomatous germ cell tumor was 25 months (range 7 to 102 months). 3. The clinical stage of patient was stage A in 9, B in 3 and C in 1, The median survival periods of clinical stage A was 27.3 months, B in 51.3 months and C in 8 months. 4. Preoperative evaluation of serum AFB & HCG was made by radioimmunoassay. Only 1 case of non-seminomatous germ cell tumor had elevated serum AFB, but 2 cases of seminoma & 1 case of non-seminomatous germ cell tumor had elevated serum HCG. 5. The average survival periods according to treatment modalities was 40 months in radiation therapy(6 cases of seminoma), 10 months in chemotherapy only(3 cases of non-seminomatous germ cell tumor), 14 months in RPLND(3 cases of non-seminomatous germ cell tumor) and 16 month in RP LND with chemotherapy(2 cases of nonseminomatous germ cell tumor).
Drug Therapy ; Follow-Up Studies* ; Germ Cells ; Humans ; Lymphoma ; Neoplasms, Germ Cell and Embryonal ; Radioimmunoassay ; Reticulum ; Seminoma ; Teratocarcinoma ; Teratoma ; Testicular Neoplasms

OBJECTIVETo investigate the clinical and pathological features of paratesticular desmoplastic small round cell tumor (DSRCT), and to improve the diagnosis and treatment of the disease.

METHODSOne case of paratesticular DSRCT was studied retrospectively and a considerable amount of related literature from Medline and Chinese journals reviewed. The patient was a 27-year-old man presenting with a painless testicular mass in the left hemiscrotum. On physical examination, a cystic mass was palpable while the testis was not in the left hemiscrotum.

RESULTSDuring the operation the paratesticular area was found full of multiple nodular tumor masses of various sizes ranging from 0.5 cm to 1.5 cm in diameter. Pathological examination showed the characteristic histological pattern of nests of small undifferentiated cells embedded in a dense fibrous stroma. The tumor presented an immunohistochemical feature of epithelial, mesenchymal as well as neural multidirectional differentiation. Following testicular tumor orchiectomy, chemotherapy was performed with DDP, VP16, ifosfamide and EPI. Three years follow-up found no tumor recurrence.

CONCLUSIONDesmoplastic small round cell tumor has a specific clinicopathologic stigmata, usually occurring in young males, for which surgical resection with chemotherapy is the treatment of choice. DSRCT located in the paratesticular region may have a better prognosis than its more frequently abdominal counterpart.

Adult ; Carcinoma, Small Cell ; diagnosis ; drug therapy ; surgery ; Combined Modality Therapy ; Fibroma, Desmoplastic ; diagnosis ; drug therapy ; surgery ; Humans ; Male ; Testicular Neoplasms ; diagnosis ; drug therapy ; surgery ; Treatment Outcome

We wanted to present the results of our experience with bilateral testis tumor and to suggest the effects of chemotherapy in suppressing the development of second primary testicular tumors. Between 1978 and 1997, 2,345 patients were treated for testicular tumor at The University of Texas M. D. Anderson Cancer Center. Of these, 2,107 had germ cell cancers. There were 22 (0.94%) cases of bilateral testicular tumor in the overall patient population and 21 (1.0%) cases among patients with germ cell cancer. We reviewed the medical records to determine the incidence of the histological subtype, the incidence of metachronous versus synchronous formation of contralateral tumors, and tumor stage in this patient population. We also examined the effect of chemotherapy in treating the first tumor and preventing the occurrence of a second tumor. Finally, we compared the effect of ultrasonography, serum tumor marker elevation, and physical examination in detecting second tumors. Only one contralateral germ cell tumor developed synchronously; all others developed metachronously. Fifty percent of first tumors were seminomas, compared to 55% of second tumors. The histologic concordance rate for first and second tumors was 35%. Tumor stage was higher among first tumors than second tumors. The majority of second tumors in patients who received chemotherapy for first malignancies tended to be metachronous seminomas. Ultrasonography detected 6 of 21 (28.6%) contralateral tumors before they were evident by physical examination or serum tumor marker elevation. Seminomas were more prevalent among patients with bilateral germ cell disease than patients with unilateral disease. Chemotherapy, when used as treatment for first tumors, may have some effect in preventing the development of nonseminomatous germ cell tumors in the contralateral testicle. Close follow-up of the contralateral testis with ultrasonography is essential for early detection of second tumors. The outcome for patients with bilateral testicular germ cell cancer is excellent, secondary to early detection.
Adolescence ; Adult ; Antineoplastic Agents/therapeutic use* ; Human ; Incidence ; Male ; Neoplasms, Multiple Primary/epidemiology ; Neoplasms, Second Primary/prevention & control* ; Neoplasms, Second Primary/epidemiology ; Testicular Neoplasms/pathology ; Testicular Neoplasms/drug therapy*

It is estimated that in 2010, 1 in every 250 adults will be a childhood cancer survivor. Today, oncological surgery, radiotherapy and chemotherapy achieve relatively high rates of remission and long-term survival, yet are often detrimental to fertility. Quality of life is increasingly important to long-term survivors of cancer, and one of the major quality-of-life issues is the ability to produce and raise normal children. Developments in the near future in the emerging field of fertility preservation in cancer survivors promise to be very exciting. This article reviews the published literature, discusses the effects of cancer treatment on fertility and presents the options available today thanks to advances in assisted-reproduction technology for maintaining fertility in male and female patients undergoing this type of treatment. The various diagnostic methods of assessing the fertility potential and the efficacy of in vitro fertilization (IVF) after cancer treatment are also presented.
Adult ; Child ; Female ; Fertility ; Humans ; Infertility ; prevention & control ; Male ; Neoplasms ; drug therapy ; radiotherapy ; surgery ; Ovarian Neoplasms ; pathology ; Ovary ; pathology ; Survivors ; Testicular Neoplasms ; pathology ; Testis ; pathology

A series of chemotherapeutic drugs that induce DNA damage, such as cisplatin (DDP), are standard clinical treatments for ovarian cancer, testicular cancer, and other diseases that lack effective targeted drug therapy. Drug resistance is one of the main factors limiting their application. Sensitizers can overcome the drug resistance of tumor cells, thereby enhancing the antitumor activity of chemotherapeutic drugs. In this study, we aimed to identify marketable drugs that could be potential chemotherapy sensitizers and explore the underlying mechanisms. We found that the alcohol withdrawal drug disulfiram (DSF) could significantly enhance the antitumor activity of DDP. JC-1 staining, propidium iodide (PI) staining, and western blotting confirmed that the combination of DSF and DDP could enhance the apoptosis of tumor cells. Subsequent RNA sequencing combined with Gene Set Enrichment Analysis (GSEA) pathway enrichment analysis and cell biology studies such as immunofluorescence suggested an underlying mechanism: DSF makes cells more vulnerable to DNA damage by inhibiting the Fanconi anemia (FA) repair pathway, exerting a sensitizing effect to DNA damaging agents including platinum chemotherapy drugs. Thus, our study illustrated the potential mechanism of action of DSF in enhancing the antitumor effect of DDP. This might provide an effective and safe solution for combating DDP resistance in clinical treatment.
Female ; Male ; Humans ; Cisplatin/pharmacology* ; Disulfiram/pharmacology* ; Testicular Neoplasms/drug therapy* ; Fanconi Anemia/drug therapy* ; Alcoholism/drug therapy* ; Drug Resistance, Neoplasm ; Cell Line, Tumor ; Substance Withdrawal Syndrome/drug therapy* ; Apoptosis ; Antineoplastic Agents/therapeutic use* ; Cell Proliferation